- Home
- TRS vs MESO Comparison
TRS vs MESO Comparison
Compare TRS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRS
- MESO
- Stock Information
- Founded
- TRS 1986
- MESO 2004
- Country
- TRS United States
- MESO Australia
- Employees
- TRS N/A
- MESO N/A
- Industry
- TRS Industrial Specialties
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRS Industrials
- MESO Health Care
- Exchange
- TRS Nasdaq
- MESO Nasdaq
- Market Cap
- TRS 1.1B
- MESO 1.2B
- IPO Year
- TRS 2007
- MESO N/A
- Fundamental
- Price
- TRS $24.52
- MESO $14.63
- Analyst Decision
- TRS Strong Buy
- MESO Strong Buy
- Analyst Count
- TRS 1
- MESO 4
- Target Price
- TRS $40.00
- MESO $13.50
- AVG Volume (30 Days)
- TRS 224.9K
- MESO 552.8K
- Earning Date
- TRS 11-04-2024
- MESO 08-28-2024
- Dividend Yield
- TRS 0.65%
- MESO N/A
- EPS Growth
- TRS N/A
- MESO N/A
- EPS
- TRS 0.64
- MESO N/A
- Revenue
- TRS $906,520,000.00
- MESO $5,902,000.00
- Revenue This Year
- TRS $4.36
- MESO $66.05
- Revenue Next Year
- TRS $4.92
- MESO $348.27
- P/E Ratio
- TRS $38.30
- MESO N/A
- Revenue Growth
- TRS 2.17
- MESO N/A
- 52 Week Low
- TRS $22.45
- MESO $1.61
- 52 Week High
- TRS $28.51
- MESO $19.15
- Technical
- Relative Strength Index (RSI)
- TRS 30.03
- MESO 64.37
- Support Level
- TRS $25.77
- MESO $12.20
- Resistance Level
- TRS $26.29
- MESO $19.15
- Average True Range (ATR)
- TRS 0.58
- MESO 0.98
- MACD
- TRS -0.18
- MESO 0.37
- Stochastic Oscillator
- TRS 7.50
- MESO 48.93
About TRS TriMas Corporation
TriMas Corp is a United States-based company that designs, manufactures, and distributes engineered and applied products. The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.